TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02373280
Drug: 7 or 14 days tailored EBMT therapy group (bismuth quadruple therapy)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)\], bismuth quadruple therapy \[Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)\] If there was no metronidazole resistance, the treatment was 7 days in duration. If metronidazole resistance was evident, treatment duration was 14 days.
Study: NCT02982161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, Dosing frequency: four times daily, Mode of administration: oral
Study: NCT00672984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
Study: NCT00382993
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet
Study: NCT00382993
Drug: Combination Product (sumatriptan succinate/naproxen sodium)
Normalized name: naproxen sodium / sumatriptan Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
Study: NCT01045980
Drug: Usual care and placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (not bioimpedance guided volume management) and Placebo
Study: NCT01061450
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg once a day
Study: NCT01247103
Drug: AZD4316
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
Study: NCT01247103
Drug: AZD4316
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
Study: NCT01061450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill once a day
Study: NCT00785330
Drug: standard GVHD prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
Study: NCT01441752
Drug: TCM
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
Study: NCT01441752
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
Study: NCT00796562
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient will receive Cy by IV once a day for 2 days.
Study: NCT01308554
Drug: Placebo: sterile normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral TAP block using 20 ml of normal sterile saline per block.
Study: NCT00302965
Drug: Frozen Plasma
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00278278
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01787357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
Study: NCT02942563
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle for 4-6 cycles,~Chemoradiation for patients who are not suitable to surgery:~Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/m², bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) or Oxaliplatin 135mg/m²plus Capecitabine 1.0/m² bid po(XELOX) of each 3 weeks cycle for 2 cycles chemotherapy before TME.~All patients will receive 6-8 cycles of mFOLFOX6 or 4-5 cycles XELOX as adjuvant chemotherapy after TME.
Study: NCT04375943
Drug: Antidiabetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verify whether the use of innovative antidiabetic therapies could modify echocardiographic parameters and influence cardiological therapy
Study: NCT01118598
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
Study: NCT00789386
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
Study: NCT01660243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2capsules) once daily for 8 weeks
Study: NCT03682978
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet.
Study: NCT00391222
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of placebo every 2 weeks and oral placebo daily
Study: NCT02387580
Drug: OZ439 Prototype 1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02387580
Drug: OZ439 Prototype 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00795821
Drug: LY2216684
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
Study: NCT00795821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose: 3 tablets QD for 10 weeks
Study: NCT03602287
Drug: Lignocaine 2% Injection 20Ml Vial (Product)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the Merocel pack 15 minutes before removal of the pack
Study: NCT03602287
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of normal saline was injected into the Merocel pack 15 minutes before removal of the pack
Study: NCT03353857
Drug: Norethindrone/ Noriday
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 1, In Period 2, 0.35 mg single dose administered as 1x0.35 mg tablet on Study Day 15 In Period 3, 0.35 mg single dose administered as 1x0.35 mg tablet at Study Day 26
Study: NCT03353857
Drug: Drospirenone, Ethinylestradiol/ Yasmin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 1, In Period 2, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 15, In Period 3, 3 mg drospirenone, 0.03 mg ethinylestradiol single dose administered as 1x3mg drospirenone, 0.03 mg ethinylestradiol tablet on Study Day 26,
Study: NCT02380976
Drug: combination drug: DW330SR, DW1030
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00461045
Drug: MRZ 0.5 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
Study: NCT00014768
Drug: leucine
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02768701
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
Study: NCT04537689
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet up to 15mg per week
Study: NCT04176835
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02249910
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
Study: NCT02303626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01548651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
Study: NCT04511728
Drug: HSK3486
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h
Study: NCT00837785
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg (two 120 mg capsules) orally three times a day
Study: NCT00837785
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg (two 120 mg capsules) orally twice a day
Study: NCT04229901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as an intravenous (IV) infusion
Study: NCT01215279
Drug: AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg oral treatment once daily for 28 days
Study: NCT01215279
Drug: Placebo to AZD2423
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment once daily for 28 days
Study: NCT00835484
Drug: OMNICEF® 300 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 300 mg, single-dose fasting
Study: NCT02799069
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
Study: NCT02627820
Drug: Isis 420915/GSK 299872
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label study in comparison to historic control.
Study: NCT00301340
Drug: 5% Lice Asphyxiator lotion - Summers Laboratories, Inc.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01471353
Drug: Sorafenib Plus Capecitabine (SorCape)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Study: NCT00357500
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00357500
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04651036
Drug: QL0605
Approvals — FDA: no, EMA: no, PMDA: no
Description: a pegfilgrastim biosimilar to US Neulasta.
Study: NCT04651036
Drug: US Neulasta
Approvals — FDA: no, EMA: no, PMDA: no
Description: US Neulasta
Study: NCT01022983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ml/kg/hours - same infusion rate as active comparator
Study: NCT02555735
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician's Choice Chemotherapy Treatment (non-guided)
Study: NCT00630955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once per day for 7 days
Study: NCT00756873
Drug: Administration of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo qd orally day 0-14
Study: NCT00756873
Drug: Administration of etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg qd orally day 0-14
Study: NCT00756873
Drug: Administration of etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
Study: NCT03333551
Drug: F18 Florbetapir (amyvid) cardiac PET/CT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with cardiac amyloidosis (AL) undergoing planned plasma cell directed chemotherapy will have F-18 florbetapir (amyvid) cardiac PET/CT imaging prior to starting chemotherapy and six months after onset of treatment.
Study: NCT03123094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT02057679
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
Study: NCT03981770
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: For maintenance of propofol anesthesia, total intravenous anesthesia was administered by using propofol (Fresenius Kabi, Austria GmbH) at a plasma target concentration (Marsh pharmacokinetic model software) of 2.5-4 μg/ml. Remifentanil (0.2-0.5 μg/kg/min) was given to all patients during the operation.
Study: NCT03804697
Drug: selective anticoagulation
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective anticoagulation group used anticoagulant once thromboelastography indicated hypercoagulable state. Conventional anticoagulation group used anticoagulant until one month after surgery routinely. The main difference was that the experimental group did not use anticoagulation if the thromboelastography indicated that the blood coagulation status was normal while the control group use anticoagulation routinely.
Study: NCT00736658
Drug: AZD1386
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Study: NCT00736658
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral admin. of doses at 11 days through a 12 days period.
Study: NCT03351296
Drug: LV5FU2
Approvals — FDA: no, EMA: no, PMDA: no
Description: LV5FU2 (Folinic Acid D, L 400 mg/m² day 1, 5FU 400 mg/m² IV bolus, 5FU 2400 mg/m² 48 hours continuous infusion)
Study: NCT03351296
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 750 mg/m² twice daily, days 1-14
Study: NCT02084654
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04762784
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone/prednisolone: started at 0.6-0. 8mg/kg.d for 2 to 4 weeks, tapered at 5mg per 1-2 weeks to equal to or less than 15mg per day in 3 months.
Study: NCT00136799
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02730533
Drug: No PPI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PPI treatment before ESD procedure
Study: NCT01814904
Drug: colestilan-M
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSAeq 6 g/day
Study: NCT00730132
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Study: NCT02241551
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles in the mFOLFIRINOX
Study: NCT01585623
Drug: SAR302503
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT00440167
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)
Study: NCT01694212
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03911037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
Study: NCT01131637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: day1\~day10:0.6ug/kg/day,10hours per day for vein infusion; week3\~week25:0.8ug/kg/day,10minutes per time per week for vein injection
Study: NCT00908128
Drug: CellCept®
Approvals — FDA: no, EMA: no, PMDA: no
Description: CellCept® Tablets, 500 mg
Study: NCT01596998
Drug: Levobupivacaine with epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
Study: NCT03155503
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT04089553
Drug: AZD4635
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Module 1, participants will receive AZD4635 75 mg capsule orally QD for first 14 days and thereafter will continue to receive 75 mg orally QD Q4W.~In Module 2, participants will receive AZD4635 50 mg / 75 mg capsule orally QD Q2W of 28-day cycle for the first 4 doses and Q4W thereafter.~In both modules, participants will receive treatment until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
Study: NCT00663481
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02330237
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000330
Drug: Opioid-Related Disorders
Normalized name: DRUGS FOR ACID RELATED DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03317444
Drug: TRC101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT03317444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral suspension
Study: NCT03058614
Drug: CEUS
Normalized name: COPRINUS MICACEUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
Study: NCT03069183
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
Study: NCT04050410
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill given as 1 dose
Study: NCT00005571
Drug: h5G1.1-mAb
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02554877
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT02478775
Drug: recombinant FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
Study: NCT01529632
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
Study: NCT01529632
Drug: NVA237
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
Study: NCT01529632
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
Study: NCT01004705
Drug: Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),
Approvals — FDA: no, EMA: no, PMDA: no
Description: A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
Study: NCT01004705
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A once daily oral dose of simvastatin for 12 weeks.
Study: NCT02476045
Drug: 5-fluorouracil,leucovorin,panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment (ARM A)
Study: NCT02476045
Drug: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment
Study: NCT00835666
Drug: PROSCAR®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 5 mg, single dose fasting
Study: NCT00729976
Drug: Ibuprofen suppository
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-10mg/Kg of ibuprofen
Study: NCT00729976
Drug: Ibuprofen Suspension
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-10mg/Kg